Anti-GP6 mAb – Research Grade (ACT017)

Anti-GP6 mAb – Research Grade (ACT017): A Potential Therapeutic Target in Thrombosis Research

Anti-GP6 monoclonal antibody (ACT017) is a research-grade antibody designed to target glycoprotein VI (GP6), a key platelet surface receptor involved in thrombus formation. GP6 plays a crucial role in platelet activation and aggregation by mediating collagen-induced signaling in damaged blood vessels. As a result, it has emerged as an important therapeutic target in the treatment of thrombotic disorders, offering a potential alternative to conventional antiplatelet therapies.

ACT017 functions by specifically binding to GP6, effectively inhibiting its interaction with collagen and preventing excessive platelet activation. This selective mechanism reduces thrombus formation without significantly impairing hemostasis, minimizing the risk of severe bleeding—a major limitation of current antithrombotic drugs. Research suggests that targeting GP6 with monoclonal antibodies like ACT017 may provide a safer and more effective strategy for managing conditions such as stroke, myocardial infarction, and venous thromboembolism.

As a research-grade antibody, ACT017 is widely used in preclinical studies to investigate GP6’s role in thrombosis and explore novel therapeutic approaches. Its specificity and high binding affinity make it an essential tool for studying platelet function, signaling pathways, and the development of innovative antithrombotic agents. This antibody’s sequence is highly similar to glenzocimab sequence.

By targeting a key player in platelet activation, ACT017 highlights the potential of monoclonal antibodies in advancing thrombosis research and developing next-generation treatments.